BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

...Coalition for Epidemic Preparedness Innovations (CEPI) to collaborate with the International Vaccine Institute and the Korea National Institute of Health...
BioCentury | Oct 27, 2017
Company News

NIH, Geom to conduct Phase I of GT-1

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Geom Therapeutics Inc. (San Diego, Calif.) partnered to conduct a Phase I trial of Geom's lead candidate GT-1 (LCB10-0200). The double-blind, placebo-controlled, dose-escalation study will...
BioCentury | Aug 18, 2017
Company News

SillaJen and NCI to evaluate Pexa-Vec with PD-L1 and CTLA-4 antibodies

SillaJen Inc. (KOSDAQ:215600) entered into a cooperative research and development agreement (CRADA) with NIH's National Cancer Institute to evaluate the biotech's Pexa-Vec pexastimogene in combination with undisclosed antibodies targeting PD-L1 and cytotoxic T-lymphocyte associated protein...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
Items per page:
1 - 4 of 4
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

...Coalition for Epidemic Preparedness Innovations (CEPI) to collaborate with the International Vaccine Institute and the Korea National Institute of Health...
BioCentury | Oct 27, 2017
Company News

NIH, Geom to conduct Phase I of GT-1

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Geom Therapeutics Inc. (San Diego, Calif.) partnered to conduct a Phase I trial of Geom's lead candidate GT-1 (LCB10-0200). The double-blind, placebo-controlled, dose-escalation study will...
BioCentury | Aug 18, 2017
Company News

SillaJen and NCI to evaluate Pexa-Vec with PD-L1 and CTLA-4 antibodies

SillaJen Inc. (KOSDAQ:215600) entered into a cooperative research and development agreement (CRADA) with NIH's National Cancer Institute to evaluate the biotech's Pexa-Vec pexastimogene in combination with undisclosed antibodies targeting PD-L1 and cytotoxic T-lymphocyte associated protein...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
Items per page:
1 - 4 of 4